The Johns Hopkins Summer Translational Oncology Program (STOP) is a 7 week fellowship for US medical students who have completed their first year of medical school. The STOP is designed to attract promising medical students at an early career stage, during which they are typically undecided about specific career plans, to the field of oncology. The strategy of this proposed program is to actively engage highly motivated students at an early point in their training by exposing them to the different facets of clinical practice, laboratory research and community outreach. The goal is to instill a lasting sense of excitement about oncology, and to encourage these students to consider postgraduate training in an oncological specialty. This proposal is designed to specifically fund trainees from medical schools that are not currently affiliated with an NCI-designated comprehensive cancer center. This program will provide a structured research experience in the oncology laboratories of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, to be supplemented by daily didactic presentations on the molecular basis of cancer, the major areas of modern cancer research, challenges in clinical oncology, and approaches to alleviating cancer health disparities. Half-day rotations on the medical oncology, surgical oncology, pediatric oncology and radiation oncology services are designed to expose fellows to outpatient and inpatient clinical practice. Students will learn about community outreach by shadowing physicians in a clinic for uninsured patients in East Baltimore. A journal club and an end of program symposium provide students with opportunities to formally present published studies and their own research findings. The two Specific Aims of this proposed educational program are to 1) provide rising second year medical students with research, clinical and outreach experiences and didactic instruction that will increase their interest in careers in oncology, and 2) to track the early, intermediate and later career stages of STOP graduates to determine the effectiveness of this educational approach

Public Health Relevance

The Johns Hopkins Summer Translational Oncology Program (STOP) is a 7 week fellowship for US medical students that is designed to promote interest in careers in oncology. The program integrates laboratory-based research, didactic learning and clinical exposure. STOP is designed to engage compassionate and committed medical students at an early career stage, during which they are typically undecided about specific career plans.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Education Projects (R25)
Project #
4R25CA171973-04
Application #
9071399
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Korczak, Jeannette F
Project Start
2013-06-04
Project End
2018-05-31
Budget Start
2016-06-01
Budget End
2017-05-31
Support Year
4
Fiscal Year
2016
Total Cost
Indirect Cost
Name
Johns Hopkins University
Department
Radiation-Diagnostic/Oncology
Type
Schools of Medicine
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21205
Miciak, Jessica J; Hirshberg, Jason; Bunz, Fred (2018) Seamless assembly of recombinant adenoviral genomes from high-copy plasmids. PLoS One 13:e0199563
Emens, Leisha A (2018) Breast Cancer Immunotherapy: Facts and Hopes. Clin Cancer Res 24:511-520
Taghipour, Mehdi; Sheikhbahaei, Sara; Trahan, Tyler J et al. (2016) Value of fourth and subsequent post-therapy follow-up 18F-FDG PET/CT scans in patients with breast cancer. Nucl Med Commun 37:602-8
Abdelfatah, Eihab; Kerner, Zachary; Nanda, Nainika et al. (2016) Epigenetic therapy in gastrointestinal cancer: the right combination. Therap Adv Gastroenterol 9:560-79
Ma, Hayley S; Greenblatt, Sarah M; Shirley, Courtney M et al. (2016) All-trans retinoic acid synergizes with FLT3 inhibition to eliminate FLT3/ITD+ leukemia stem cells in vitro and in vivo. Blood 127:2867-78
Li, L; Pongtornpipat, P; Tiutan, T et al. (2015) Synergistic induction of apoptosis in high-risk DLBCL by BCL2 inhibition with ABT-199 combined with pharmacologic loss of MCL1. Leukemia 29:1702-12
Michailidi, Christina; Hayashi, Masamichi; Datta, Sayantan et al. (2015) Involvement of epigenetics and EMT-related miRNA in arsenic-induced neoplastic transformation and their potential clinical use. Cancer Prev Res (Phila) 8:208-21
Emens, Leisha A; Middleton, Gary (2015) The interplay of immunotherapy and chemotherapy: harnessing potential synergies. Cancer Immunol Res 3:436-43